TickerFacts.

Company research / CPIX

Cumberland Pharmaceuticals Inc (CPIX)

Build a valuation ↗↓ Download CSV

SEC name CUMBERLAND PHARMACEUTICALS INC · CIK 0001087294 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated TN
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Cumberland Pharmaceuticals Inc reported revenue of $44.52M. Revenue grew 17.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $39.90M.

Key ratios (year ended 2025-12-31)

85.0%
Gross margin (computed)
-6.3%
Operating margin
-6.4%
Net margin
-11.4%
Return on year-end equity
17.6%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K/A (current report) · 2026-09-11

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$39.90M$44.52M$37.87M$39.55M$42.01M$35.05M$35.84M$32.41M$28.80M$40.38M$32.48M
Cost of Revenuen/a$6.67M$6.59M$6.07M$9.12M$8.81M$8.65M$7.42M$6.02M$7.37M$5.96M
Gross Profit (computed)n/a$37.85M$31.28M$33.49M$32.89M$26.23M$27.19M$24.99M$22.79M$33.01M$26.52M
R&D Expensen/a$5.57M$4.82M$5.83M$6.69M$5.68M$5.77M$6.87M$7.58M$4.28M$3.19M
Operating Incomen/a-$2.79M-$6.43M-$9.55M-$5.70M-$7.68M-$6.38M-$9.29M-$11.17M-$4.08M-$1.43M
Depreciation & Amortizationn/a$4.15M$4.90M$4.94M$5.33M$4.61M$4.75M$4.40M$2.98M$2.65M$2.40M
EBITDAn/a$1.35M-$1.53M-$4.62M-$376.8K-$3.07M-$1.63M-$4.88M-$8.19M-$1.43M$963.8K
Net Income-$10.92M-$2.84M-$6.48M-$6.28M-$5.57M-$3.51M-$3.34M-$3.54M-$6.96M-$7.98M-$944.7K
EPS (Diluted)n/a-$0.19-$0.46-$0.44-$0.38-$0.24-$0.22-$0.23-$0.45-$0.50-$0.06
Total Assets$62.88M$76.82M$75.58M$81.78M$92.93M$84.46M$96.46M$104.55M$112.69M$93.23M$93.40M
Total Liabilities$45.77M$52.28M$53.04M$52.52M$56.95M$41.86M$49.59M$53.46M$57.12M$29.31M$20.28M
Shareholders' Equity$17.44M$24.88M$22.85M$29.60M$36.27M$42.81M$46.99M$51.12M$55.84M$64.12M$73.25M
Cash & Equivalents$3.86M$11.44M$17.96M$18.32M$19.76M$27.04M$24.75M$28.21M$27.94M$45.41M$34.51M
Operating Cash Flow$746.0K$4.93M-$612.2K$6.09M$8.45M$6.34M$5.42M$3.06M$3.11M-$557.7K$569.5K
Capital Expenditures$62.1K$97.9K$66.5K$281.3K$102.1K$103.5K$140.8K$246.2K$455.6K$276.0K$130.9K
Free Cash Flow$683.9K$4.83M-$678.6K$5.81M$8.35M$6.24M$5.27M$2.81M$2.66M-$833.7K$438.6K
Share Repurchases$71.4K$263.5K$579.0K$740.5K$1.05M$1.39M$1.85M$3.49M$2.88M$3.72M$2.52M
Shares Outstanding14.98M14.96M13.95M14.12M14.37M14.74M14.99M15.26M15.48M16.07M16.07M
Weighted Average Diluted Sharesn/a14.85M14.06M14.30M14.56M14.90M15.16M15.40M15.61M15.91M16.24M
EPS (Basic)n/a-$0.19-$0.46-$0.44-$0.38-$0.24-$0.22-$0.23-$0.45-$0.50-$0.06

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView